Sign In
Last checked at 
21 Sep 2011 16:49
21 September 2011 |
Surgical Innovations Group plc
("SI" or "the Group")
Issue of Equity
Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of innovative medical devices, today announces that following his exercise of options it has issued and allotted 135,000 ordinary shares of 3.5p each on 21 September 2011, to Graham Bowland, Chief Executive, to be held in his SIPP.
Details of the Mr Bowland's options exercised and resulting shareholding is as follows:-
Number of options | Exercise price | Total shareholding following issue | Total shareholding percentage of enlarged issued share capital | |
Graham Bowland | 135,000 | 3.5p | 4,528,498 | 1.12% |
Accordingly Application has been made to the London Stock Exchange for the 135,000 New Ordinary Shares of 3.5p each to be admitted to trading on AIM ("Admission"). It is expected that such Admission will occur on 28 September 2011. The new ordinary shares rank pari passu with the existing shares of the Company.
Following Admission the total number of ordinary shares in issue will be 394,872,902 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the purposes of the Disclosure and Transparency Rules.
- Ends -
Enquiries:
Surgical Innovations Group plc | |
Doug Liversidge, Non-Executive Chairman | |
Graham Bowland, Chief Executive Officer | Tel: +44 (0) 113 230 7597 |
graham.bowland@surginno.co.uk | www.surginno.com |
Seymour Pierce Limited | |
Freddy Crossley / Sarah Jacobs | Tel: +44 (0) 20 7107 8000 |
Corporate Broking | |
Marianne Woods / Jacqui Briscoe | www.seymourpierce.com |
Media enquiries: | |
The Communications Portfolio | |
Ariane Comstive / Caolan Mahonariane.comstive@communications-portfolio.co.uk | Tel: +44 (0) 20 7536 2028Mob: +44 (0) 7785 922 354 |
Enquiries:
Surgical Innovations Group plcDoug Liversidge, ChairmanGraham Bowland, Chief Executive Officer Tel: +44 (0) 113 230 7597graham.bowland@surginno.co.uk www.surginno.com
Seymour Pierce LimitedFreddy Crossley / Sarah Jacobs Tel: +44 (0) 20 7107 8000Corporate BrokingMarianne Woods / Jacqueline Briscoe www.seymourpierce.com
Media enquiries:The Communications PortfolioAriane Comstive / Caolan Mahon Tel: +44 (0) 20 7536 2028 / 2029ariane.comstive@communications-portfolio.co.uk Mob: +44 (0) 7785 922 354
Notes to Editors:
About Surgical Innovations Group plc
Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery (MIS) and industrial markets.
As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.
Over 145 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection molding and manufacturing equipment, producing products to the highest quality standards.
The Group's patented products are sold through three main channels:
SI brand | Through an established network of 45 distribution partners, Surgical Innovations branded products are sold in all major medical markets including North America, Europe, South Africa, the Middle East, South-east Asia and Australia. |
OEM and IP | The Group supplies large medical device companies on an OEM basis, collecting sales fees as well as IP license and royalty fees. Clients include Teleflex Medical, Olympus and CareFusion. |
Industrial
| SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, such as turbines, in situ with minimum disassembly and downtime. |
For more information, see www.surginno.com
Follow the stocks
